Microbot Medical (NASDAQ:MBOT – Get Free Report) released its quarterly earnings data on Friday. The biotechnology company reported ($0.09) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.01), FiscalAI reports. The business had revenue of $0.07 million during the quarter, compared to the consensus estimate of $0.01 million.
Microbot Medical Price Performance
MBOT traded down $0.05 on Friday, reaching $0.98. The company’s stock had a trading volume of 867,209 shares, compared to its average volume of 1,297,094. Microbot Medical has a 1 year low of $0.93 and a 1 year high of $2.85. The business’s 50 day moving average is $1.17 and its 200 day moving average is $1.80. The stock has a market cap of $65.70 million, a price-to-earnings ratio of -4.08 and a beta of 1.07.
Analyst Ratings Changes
MBOT has been the subject of several analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $12.00 target price on shares of Microbot Medical in a research report on Wednesday, October 21st. Wall Street Zen downgraded Microbot Medical from a “sell” rating to a “strong sell” rating in a report on Saturday, October 24th. Weiss Ratings lowered Microbot Medical from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, November 4th. B. Riley Financial initiated coverage on Microbot Medical in a report on Friday, September 11th. They issued a “buy” rating and a $4.00 price target for the company. Finally, UBS Group set a $2.50 price objective on shares of Microbot Medical in a research report on Friday, October 23rd. Five analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Microbot Medical currently has a consensus rating of “Moderate Buy” and an average target price of $5.08.
Get Our Latest Stock Report on MBOT
About Microbot Medical
Microbot Medical is a medical-device company developing robotic technologies for endovascular procedures. Its work focuses on tools intended to help physicians navigate blood vessels and perform minimally invasive interventions. The company’s lead platform, LIBERTY, is a remotely operated robotic system designed for endovascular procedures. The system is intended to work with guidewires and catheters and to support physicians in controlling these devices during treatment. Microbot Medical is based in the United States and has roots in Israel.
Read More
- Five stocks we like better than Microbot Medical
- Nu Holdings Earnings Show a Compounder Priced Like a Brazil Bet
- Game On: The Hidden Value in Take-Two’s Stock
- LightPath Technologies’ Record Backlog Highlights a Bigger Defense Opportunity
- A 10-Stock Strategy That Balances AI Growth With Cash Flow
Receive News & Ratings for Microbot Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Microbot Medical and related companies with MarketBeat.com's FREE daily email newsletter.
